Comparative Pharmacology
Head-to-head clinical analysis: METAGLIP versus QTERN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METAGLIP versus QTERN.
METAGLIP vs QTERN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Metformin decreases hepatic glucose production and intestinal absorption, and improves insulin sensitivity; glipizide stimulates insulin secretion from pancreatic beta cells by inhibiting ATP-sensitive potassium channels.
QTERN is a fixed-dose combination of dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and saxagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor. Dapagliflozin reduces renal glucose reabsorption, increasing urinary glucose excretion. Saxagliptin increases incretin hormones, enhancing insulin secretion and decreasing glucagon levels.
Oral: Initial 2.5 mg/250 mg once daily with breakfast, titrate gradually to maximum 20 mg/2000 mg per day in divided doses twice daily.
One tablet orally twice daily; each tablet contains dapagliflozin 10 mg and saxagliptin 5 mg.
None Documented
None Documented
Terminal elimination half-life: 12-15 hours; clinically, dosing adjustments required in renal impairment with CrCl <60 mL/min
Terminal half-life approximately 5 hours; supports twice-daily dosing.
Renal: 90-95% unchanged; biliary/fecal: <5% as metabolites
Fecal (59% unchanged) and renal (42% unchanged, primarily via tubular secretion).
Category C
Category C
Antidiabetic Combination
Antidiabetic Combination